Anhydrous hydrocolloid matrices contain one or more encapsulated therapeutic agents, including an acne agent and/or skin conditioning agent. The anhydrous hydrocolloid matrices are used as acne treatment dressings alone or in a laminate with a water-impermeable or semi-water impermeable backing and a release liner. The anhydrous hydrocolloid matrices are made using a premix of viscosity modifiers and hydrocarbon emollients and the one or more therapeutic agents, which are mixed via high shear mixing to form the premix. The resulting anhydrous hydrocolloid matrices include the one or more therapeutic agents which are encapsulated and homogeneously distributed therein.

The present invention provides a pharmaceutical preparation comprising a layer-by-layer thin film that is produced by alternately layering a polycation and a polyanion, and a drug loaded onto the layer-by-layer thin film. As a result, a pharmaceutical preparation with a prolonged duration of drug action with a single dose is provided.

A method for manufacturing a plurality of pharmaceutical agent delivery patch devices includes: providing a supply web including an active layer containing a pharmaceutically active agent; and cutting the supply web to form cut lines through the active layer. The cut lines define in the active layer: a first active layer patch having a first peripheral edge formed by the cutting step; and a second active layer patch having a second peripheral edge formed by the cutting step. The first and second peripheral edges each include a corner portion. At least a first segment of the first peripheral edge and an opposing second segment of the second peripheral edge are formed by a shared one of the cut lines.

The present invention relates to a synthesis method of preventing the formation of impurities and byproducts in the synthesis of tenofovir disoproxil fumarate (Teno-DF) used as a medicine for hepatitis B and HIV treatment due to its function to promote bioactivities. In the synthesis method of the present invention, an ion-exchange resin (Dowex 50W hydrogen form, sulfonic acidic cation exchange resin) is used to enhance the yield and purity of the compound. The present invention also relates to a method of preparing an oral dissolving film dosage form in the manufacture of a medicine using the tenofovir compound with high purity obtained by the synthesis method of the present invention as an effective ingredient.

A hydrogel nanocomposite based acne treatment patch loaded with doxycycline and a method of developing thereof is described herein. The present invention relates to the preparation of biocompatible hydrogel matrix comprising polyvinyl alcohol, linseed mucilage extract, nano zinc-oxide crosslinked dually via covalent linkages and free radical polymerization by electronic beam exposure. The pore size of the hydrogel acne patch ranges between 0.1-0.5 μm. The doxycycline loaded acne patches were able to inhibit the growth of S. aureus in an in-vitro bacterial growth inhibition assay.

Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.

Pharmaceutical compositions having enhanced active component permeation properties are described.

The present application relates to a medical hydrogel comprising nanofibrillar cellulose, wherein the content of nanofibrillar cellulose in the hydrogel is in the range of 1-3.5% (w/w), and the nanofibrillar cellulose comprises anionic nanofibrillar cellulose having an average fibril diameter of 200 nm or less, and to a method for preparing thereof. The present application also relates to the medical hydrogel for use for inducing vascularization in wounds and/or for treating deep wounds of dermis and/or below tissue.

Provided is a felbinac-containing external patch which can exhibit high drug release properties, low skin irritation, and high drug stability, wherein felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including a styrene-isoprene-styrene block copolymer, an alicyclic saturated hydrocarbon resin, a softener, and diethyl sebacate, and does not contain L-menthol. Specifically, in the felbinac-containing external patch, 0.1 to 10% by weight of felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including 10 to 30% by weight of a styrene-isoprene-styrene block copolymer, 10 to 50% by weight of an alicyclic saturated hydrocarbon resin, 10 to 75% by weight of a softener, and 0.1 to 10% by weight of diethyl sebacate.

Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.